$54.65
0.39% today
Nasdaq, Sep 08, 04:19 pm CET
ISIN
CH0334081137
Symbol
CRSP

CRISPR Therapeutics AG Stock price

$54.86
-0.73 1.31% 1M
+11.02 25.14% 6M
+15.50 39.38% YTD
+9.61 21.24% 1Y
-8.88 13.93% 3Y
-27.16 33.11% 5Y
+40.77 289.35% 10Y
+40.77 289.35% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
+2.12 4.02%
ISIN
CH0334081137
Symbol
CRSP
Industry

Key metrics

Basic
Market capitalization
$5.0b
Enterprise Value
$3.3b
Net debt
positive
Cash
$1.7b
Shares outstanding
88.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
131.1 | 120.3
EV/Sales
85.9 | 78.8
EV/FCF
negative
P/B
2.9
Financial Health
Equity Ratio
86.2%
Return on Equity
-19.0%
ROCE
-23.7%
ROIC
-155.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$38.1m | $41.5m
EBITDA
$-437.3m | $-493.9m
EBIT
$-456.2m | $-606.5m
Net Income
$-467.8m | $-546.4m
Free Cash Flow
$-350.6m
Growth (TTM | estimate)
Revenue
-81.2% | 11.2%
EBITDA
-30.5% | -10.4%
EBIT
-28.6% | -30.0%
Net Income
-76.0% | -49.2%
Free Cash Flow
-175.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,149.1% | -1,190.5%
EBIT
-1,199.0%
Net
-1,229.4% | -1,317.2%
Free Cash Flow
-921.3%
More
EPS
$-5.4
FCF per Share
$-4.0
Short interest
28.9%
Employees
393
Rev per Employee
$90.0k
Show more

Is CRISPR Therapeutics AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

CRISPR Therapeutics AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a CRISPR Therapeutics AG forecast:

22x Buy
61%
13x Hold
36%
1x Sell
3%

Analyst Opinions

36 Analysts have issued a CRISPR Therapeutics AG forecast:

Buy
61%
Hold
36%
Sell
3%

Financial data from CRISPR Therapeutics AG

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
38 38
81% 81%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 188 188
13% 13%
493%
- Research and Development Expense 307 307
10% 10%
806%
-437 -437
30% 30%
-1,149%
- Depreciation and Amortization 19 19
3% 3%
50%
EBIT (Operating Income) EBIT -456 -456
29% 29%
-1,199%
Net Profit -468 -468
76% 76%
-1,229%

In millions USD.

Don't miss a Thing! We will send you all news about CRISPR Therapeutics AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CRISPR Therapeutics AG Stock News

Positive
Seeking Alpha
6 days ago
CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a winning lottery ticket, that doesn't mean you negate grand strategy. Getting lucky may get you rich, but strategy establishes you as wealthy. Risks demand a portfolio that's at least resilient and at ...
Neutral
GlobeNewsWire
6 days ago
ZUG, Switzerland and BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in September.
Positive
The Motley Fool
10 days ago
Small biopharma story stocks just aren't paying off like they used to. Maybe there are just too many of them, with each one working on a medical breakthrough that's statistically unlikely to even come close to an approval.
More CRISPR Therapeutics AG News

Company Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Samarth Kulkarni
Employees 393
Founded 2013
Website crisprtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today